Numbers and cytotoxicities of CD3<sup>+</sup>CD56<sup>+</sup>T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia

Guo, Weidong; Chen, Xing; Dong, Aishu; Lin, Xiaoji; Zhu, Bo; He, Min; Yao, Rongxing

doi:10.4161/cbt.25938

Cited by 17 publications

(24 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In acute leukemia, and in particular in the case of acute myeloid leukemia (AML), particular focus has been placed on NK cells with several groups identifying functional links between NK cell activities and AML progression . Likewise, T cells have been studied in depth and in several studies shown to be critical players in the progression of AML .…”

Section: Introductionmentioning

confidence: 99%

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia

Alcasid

Gotlib

et al. 2017

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia

Alcasid

Gotlib

et al. 2017

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…Primarily expressed in neuroendocrine, natural killer, and T cell lineages [ 3 ], aberrant CD56 expression is seen in a variety of hematological malignancies (e.g. multiple myeloma, myelocytic and lymphocytic leukemia) as well as solid tumors (most notably small cell lung cancer [SCLC], Merkel cell carcinoma [MCC], and ovarian cancer) [ 4 – 8 ]. Indeed, for solid tumors, CD56 serves as a diagnostic biomarker to identify those of neuroendocrine origin, including MCC and SCLC [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

et al. 2016

View full text Add to dashboard Cite

SummaryBackground IMGN901 is a CD56-targeting antibody-drug conjugate designed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1 study investigated the safety, tolerability, pharmacokinetics, and preliminary activity of IMGN901 in patients with CD56-expressing solid tumors. Methods Patients were enrolled in cohorts of escalating IMGN901 doses, administered intravenously, on 3 consecutive days every 21 days. A dose-expansion phase accrued patients with small cell lung cancer (SCLC), Merkel cell carcinoma (MCC), or ovarian cancer. Results Fifty-two patients were treated at doses escalating from 4 to 94 mg/m2/day. The maximum tolerated dose (MTD) was determined to be 75 mg/m2. Dose-limiting toxicities included fatigue, neuropathy, headache or meningitis-like symptoms, chest pain, dyspnea, and myalgias. In the dose-expansion phase (n = 45), seven patients received 75 mg/m2 and 38 received 60 mg/m2 for up to 21 cycles. The recommended phase 2 dose (RP2D) was established at 60 mg/m2 during dose expansion. Overall, treatment-emergent adverse events (TEAEs) were experienced by 96.9 % of all patients, the majority of which were Grade 1 or 2. The most commonly reported Grade 3 or 4 TEAEs were hyponatremia and dyspnea (each 8.2 %). Responses included 1 complete response (CR), 1 clinical CR, and 1 unconfirmed partial response (PR) in MCC; and 1 unconfirmed PR in SCLC. Stable disease was seen for 25 % of all evaluable patients who received doses ≥60 mg/m2. Conclusions The RP2D for IMGN901 of 60 mg/m2 administered for 3 consecutive days every 3 weeks was associated with an acceptable tolerability profile. Objective responses were observed in patients with advanced CD56+ cancers.

show abstract

“…Circulating T cells are composed of various subsets. Several of these specific T cell subsets, including regulatory T cells, CD3+CD56+ cells, and CD3+CD5+ cells, have been found to differ among subsets of patients with AML [ 8 9 10 23 24 ]. In this study, the percentages and counts of pan T cells and traditional T cell subsets (CD4+ cells and CD8+ cells) at diagnosis were similar to those in a healthy population and were not associated with clinical outcomes [ 11 25 ].…”

Section: Discussionmentioning

confidence: 99%

The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia

et al. 2018

View full text Add to dashboard Cite

BackgroundTumor-infiltrating lymphocytes, which form a part of the host immune system, affect the development and progression of cancer. This study investigated whether subsets of lymphocytes reflecting host-tumor immunologic interactions are related to the prognosis of patients with acute myeloid leukemia (AML).MethodsLymphocyte subsets in the peripheral blood of 88 patients who were newly diagnosed with AML were analyzed by quantitative flow cytometry. The relationships of lymphocyte subsets with AML subtypes, genetic risk, and clinical courses were analyzed.ResultsThe percentages of T and NK cells differed between patients with acute promyelocytic leukemia (APL) and those with AML with myelodysplasia-related changes. In non-APL, a high proportion of NK cells (>16.6%) was associated with a higher rate of death before remission (P=0.0438), whereas a low proportion of NK cells (≤9.4%) was associated with higher rates of adverse genetic abnormalities (P=0.0244) and relapse (P=0.0567). A multivariate analysis showed that the lymphocyte subsets were not independent predictors of survival.ConclusionLymphocyte subsets at diagnosis differ between patients with different specific subtypes of AML. A low proportion of NK cells is associated with adverse genetic abnormalities, whereas a high proportion is related to death before remission. However, the proportion of NK cells may not show independent correlations with survival.

show abstract

Numbers and cytotoxicities of CD3⁺CD56⁺T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia

Cited by 17 publications

References 20 publications

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia

Contact Info

Product

Resources

About

Numbers and cytotoxicities of CD3+CD56+T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia

Cited by 17 publications

References 20 publications

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia

The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors

The prognostic impact of lymphocyte subsets in newly diagnosed acute myeloid leukemia

Contact Info

Product

Resources

About

Numbers and cytotoxicities of CD3⁺CD56⁺T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia